Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 1...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2020-08-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/26/8/19-1499_article |
| _version_ | 1818216281192529920 |
|---|---|
| author | Marie Jaspard Nathalie Butel Najoua El Helali Dhiba Marigot-Outtandy Helene Guillot Gilles Peytavin Nicolas Veziris Bahram Bodaghi Philippe Flandre Gregoire Petitjean Eric Caumes Valerie Pourcher |
| author_facet | Marie Jaspard Nathalie Butel Najoua El Helali Dhiba Marigot-Outtandy Helene Guillot Gilles Peytavin Nicolas Veziris Bahram Bodaghi Philippe Flandre Gregoire Petitjean Eric Caumes Valerie Pourcher |
| author_sort | Marie Jaspard |
| collection | DOAJ |
| description | Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 13 months. In 33 (58%) patients, neurologic or ophthalmologic signs developed, and 18 (32%) had confirmed peripheral neuropathy, which for 78% was irreversible at 12 months after the end of TB treatment despite linezolid withdrawal. Among the 19 patients who underwent ophthalmologic evaluation, 14 patients had optic neuropathy that fully reversed for 2. A total of 16 (33%) of 49 patients had a linezolid trough concentration >2 mg/L, and among these, 14 (88%) experienced adverse effects. No significant association was found between trough concentration and neurologic toxicity. These findings suggest the need to closely monitor patients for neurologic signs and discuss optimal duration of linezolid treatment. |
| first_indexed | 2024-12-12T06:49:29Z |
| format | Article |
| id | doaj.art-07c3eea4c0164c308a632166f0bd3b7a |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-12T06:49:29Z |
| publishDate | 2020-08-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-07c3eea4c0164c308a632166f0bd3b7a2022-12-22T00:34:05ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592020-08-012681792180010.3201/eid2608.191499Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, FranceMarie JaspardNathalie ButelNajoua El HelaliDhiba Marigot-OuttandyHelene GuillotGilles PeytavinNicolas VezirisBahram BodaghiPhilippe FlandreGregoire PetitjeanEric CaumesValerie PourcherLinezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 13 months. In 33 (58%) patients, neurologic or ophthalmologic signs developed, and 18 (32%) had confirmed peripheral neuropathy, which for 78% was irreversible at 12 months after the end of TB treatment despite linezolid withdrawal. Among the 19 patients who underwent ophthalmologic evaluation, 14 patients had optic neuropathy that fully reversed for 2. A total of 16 (33%) of 49 patients had a linezolid trough concentration >2 mg/L, and among these, 14 (88%) experienced adverse effects. No significant association was found between trough concentration and neurologic toxicity. These findings suggest the need to closely monitor patients for neurologic signs and discuss optimal duration of linezolid treatment.https://wwwnc.cdc.gov/eid/article/26/8/19-1499_articleTuberculosisMDR-XDRlinezolidneuropathypharmacokineticstuberculosis and other mycobacteria |
| spellingShingle | Marie Jaspard Nathalie Butel Najoua El Helali Dhiba Marigot-Outtandy Helene Guillot Gilles Peytavin Nicolas Veziris Bahram Bodaghi Philippe Flandre Gregoire Petitjean Eric Caumes Valerie Pourcher Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France Emerging Infectious Diseases Tuberculosis MDR-XDR linezolid neuropathy pharmacokinetics tuberculosis and other mycobacteria |
| title | Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France |
| title_full | Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France |
| title_fullStr | Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France |
| title_full_unstemmed | Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France |
| title_short | Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France |
| title_sort | linezolid associated neurologic adverse events in patients with multidrug resistant tuberculosis france |
| topic | Tuberculosis MDR-XDR linezolid neuropathy pharmacokinetics tuberculosis and other mycobacteria |
| url | https://wwwnc.cdc.gov/eid/article/26/8/19-1499_article |
| work_keys_str_mv | AT mariejaspard linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT nathaliebutel linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT najouaelhelali linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT dhibamarigotouttandy linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT heleneguillot linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT gillespeytavin linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT nicolasveziris linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT bahrambodaghi linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT philippeflandre linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT gregoirepetitjean linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT ericcaumes linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance AT valeriepourcher linezolidassociatedneurologicadverseeventsinpatientswithmultidrugresistanttuberculosisfrance |